Thus, the outcomes of this study suggest that αSLAMF6 and ibrutinib should be considered as a combination therapy for CLL and possibly other SLAMF6 expressing B cell tumors. Here, SLAMF6 is linked to B-cell chronic lymphocytic leukemia.